(Lodelcizumab)Biosimilar Reference Antibody-GS40397

货号：GS40397

Lodelcizumab is a humanized monoclonal antibody that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, it prevents the protein from interacting with the low-density lipoprotein receptor (LDLR) on the surface of liver cells. This inhibition reduces the degradation of LDLR, leading to an increase in the number of LDLRs available to clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream. It is developed as a lipid-lowering therapeutic for the management of hypercholesterolemia and other metabolic disorders associated with elevated LDL-C, aiming to reduce cardiovascular risk.